Skip to Main content Skip to Navigation
New interface
Journal articles

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism

Abstract : Spironolactone, which is a potent mineralocorticoid receptor antagonist, represents the first line medical treatment of primary aldosteronism (PA). As spironolactone is also an antagonist of the androgen and progesterone receptor, it may present side effects, especially in male patients. In case of intolerance to spironolactone, amiloride may be used to control hypokaliemia and we suggest that eplerenone, which is a more selective but less powerful antagonist of the mineralocorticoid receptor, be used in case of intolerance to spironolactone and insufficient control of hypertension by amiloride. Specific calcic inhibitors and thiazide diuretics may be used as second or third line therapy. Medical treatment of bilateral forms of PA seem to be as efficient as surgical treatment of lateralized PA for the control of hypertension and the prevention of cardiovascular and renal morbidities. This allows to propose medical treatment of PA to patients with lateralized forms of PA who refuse surgery or to patients with PA who do not want to be explored by adrenal venous sampling to determine whether they have a bilateral or lateralized form.
Complete list of metadata
Contributor : Céline DUPARC Connect in order to contact the contributor
Submitted on : Thursday, December 19, 2019 - 5:31:37 PM
Last modification on : Friday, September 30, 2022 - 11:00:10 AM




Antoinette Pechère-Bertschi, Daniel Herpin, Hervé Lefebvre. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism. Annales d'Endocrinologie, 2016, 77 (3), pp.226-234. ⟨10.1016/j.ando.2016.01.010⟩. ⟨hal-02420223⟩



Record views